Are neutrophil/lymphocyte ratio and Platelet/lymphocyte ratio associated with prognosis in patients with HER2-positive early breast cancer receiving adjuvant trastuzumab?

Journal of B.U.ON.

Volumn 20, Issue 3, 2015, Pages 714-722

  Ulas, Arife ^a   Avci, Nilufer ^b   Kos, Tugba ^c   Cubukcu, Erdem ^d   Olmez, Omer Fatih ^d   Bulut, Nilufer ^d   Degirmenci, Mustafa ^d  

^a ATATURK TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b Balikesir Government Hospital   (Turkey)

^c DUZCE UNIVERSITY   (Turkey)

^d Ali Osman Sonmez Oncology Hospital   (Turkey)

Author keywords

Breast cancer; HER2 positive; Lymphocytes; Neutrophil; Platelet

Indexed keywords

TRASTUZUMAB; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; TUMOR MARKER;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; DISEASE FREE SURVIVAL; EARLY CANCER; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; EVALUATION STUDY; FEMALE; FOLLOW UP; HUMAN; INVESTIGATIVE PROCEDURES; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL LYMPHOCYTE RATIO; OVERALL SURVIVAL; PLATELET LYMPHOCYTE RATIO; RETROSPECTIVE STUDY; SURVIVAL RATE; TUMOR VOLUME; ADJUVANT CHEMOTHERAPY; ANTAGONISTS AND INHIBITORS; BLOOD; BREAST NEOPLASMS; CLINICAL TRIAL; DISEASE COURSE; IMMUNOLOGY; KAPLAN MEIER METHOD; LYMPHOCYTE; LYMPHOCYTE COUNT; METABOLISM; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; NEUTROPHIL; PATHOLOGY; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; THROMBOCYTE; THROMBOCYTE COUNT; TIME; TREATMENT OUTCOME; TURKEY;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BLOOD PLATELETS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOCYTE COUNT; LYMPHOCYTES; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEUTROPHILS; PLATELET COUNT; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL; TURKEY;

EID: 84938695006     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244:707-712.
2. Perou CM, Sortie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000; 406:747-752.
3. Gabos Z, Thorns J, Ghosh S et al. The association between biological subtype and locoregional recurrence in newly diagnosed breast cancer. Breast Cancer Res Treat 2010; 124:187-194.
4. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against her 2 for metastatic breast cancer that overexpresses her 2. N Engl J Med 2001; 344:783-892.
5. Baselga J, Perez EA, Pienkowski T, Bell R. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer. Oncologist 2006; 11 (SUPPL. 1):4-12.
6. Smith I, Procter M, Gelber RD et al. 2-year follow up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007; 369:29-36.
7. Gianni L, Dafni U, Gelber RD et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol 2011; 12:236-244.
8. Goldhirsch A, Piccart-Gebhart MJ, Procter M. HERA TRIAL: 2 years versus 1 year of trastuzumab after adjuvant chemotherapy in women with HER2-positive early breast cancer at 8 years of median follow up. Cancer Res 2013; 72 (24 suppl):S5-2 [OR 2-5?].
9. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420:860-867.
10. Ma JP, Wang Z, Lin JW et al. Neutrophil-lymphocyte ratio as a prognostic factor in gastric cancer. Zhong-hua Wei Chang Wai Ke Za Zhi 2011; 14:944-947.
11. Keizman D, Ish-Shalom M, Huang P et al. The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma. Eur J Cancer 2012; 48:202-208.
12. Schmidt H, Bastholt L, Geertsen P et al. Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model. Br J Cancer 2005; 93:273-278.
13. Teramukai S, Kitano T, Kishida Y et al. Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: an analysis of Japan Multinational Trial Organisation LC00-03. Eur J Cancer 2009; 45:1950-1958.
14. Unal D, Eroglu C, Kurtul N., Oguz A, Tasdemir A. Are neutrophil/lymphocyte and platelet/lymphocyte rates in patients with non-small cell lung cancer associated with treatment response and prognosis? Asian Pac J Cancer Prev 2013; 14:5237-5242.
15. Kaplan KL, Broekman MJ, Chernoff A, Lesznik G.R., Drillings M. Platelet alpha-granule proteins: studies on release and subcellular localization. Blood 1979; 53:604-618.
16. Dubernard V, Arbeille BB, Lemesle M.B., Legrand C. Evidence for an alpha-granular pool of the cytoskel-etal protein alpha-actinin in human platelets that redistributes with the adhesive glycoprotein thrombospondin-1 during the exocytotic process. Arterioscler Thromb Vase Biol 1997; 17:2293-2305.
17. Qian X, Tuszynski GP. Expression of thrombospondin-1 in cancer: a role in tumor progression. Proc Soc Exp Biol Med 1996; 212:199-207.
18. Raungkaewmanee S, Tangjitgamol S, Manusirivithaya S., Srijaipracharoen S, Thavaramara T. Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer. J Gynecol Oncol 2012; 23:265-273.
19. Asher V, Lee J, Innamaa A., Bali A. Preoperative platelet lymphocyte ratio as an independent prognostic marker in ovarian cancer. Clin Transi Oncol 2011; 13:499-503.
20. Feng JF, Huang Y, Chen QX. Preoperative platelet lymphocyte ratio (PLR) is superior to neutrophil lymphocyte ratio (NLR) as a predictive factor in patients with esophageal squamous cell carcinoma. World J Surg Oncol 2014; 12:58.
21. Aaltomaa S, Lipponen P, Eskelinen M et al. Lymphocyte infiltrates as a prognostic variable in female breast cancer. Eur J Cancer 1992; 28:859-864.
22. Mahmoud SM, Paish EC, Powe DG et al. Tumor-infiltrating cd8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 2011; 29:1949-1955.
23. Azab B, Bhatt VR, Phookan J et al. Usefulness of the neutrophil-to-lymphocyte ratio in predicting short-and long-term mortality in breast cancer patients. Ann Surg Oncol 2012; 19:217-224.
24. Dirican A, Kucukzeybek BB, Alacacioglu A et al. Do the derived neutrophil to lymphocyte ratio and the neutrophil to lymphocyte ratio predict prognosis in breast cancer? Int J Clin Oncol 2014; 18:18-26.
25. Noh H, Eomm M, Han A. Usefulness of pretreatment neutrophil to lymphocyte ratio in predicting disease-specific survival in breast cancer patients. J Breast Cancer 2013; 16:55-59.
26. Kuang D-M, Zhao Q., Wu Y et al. Peritumoral neutrophils link inflammatory response to disease progression by fostering angiogenesis in hepatocellular carcinoma. J Hepatol 2011; 54:948-955.
27. Scapini P, Morini M, Tecchio C et al. Cxcl1/macrophage inflammatory protein-2-induced angiogenesis in vivo is mediated by neutrophil-derived vascular endothelial growth factor-a. J Immunol 2004; 172:5034-5040.
28. Munder M, Schneider H, Luckner C et al. Suppression of t-cell functions by human granulocyte arginase. Blood 2006; 108:1627-1634.
29. Schmielau J, Finn OJ. Activated granulocytes and granulocyte derived hydrogen peroxide are the underlying mechanism of suppression of T-cell function in advanced cancer patients. Cancer Res 2001; 61:4756-4760.
30. Campiglio M, Bufalino R, Sasso M et al. Effect of adjuvant trastuzumab treatment in conventional clinical setting: an observational retrospective multicenter Italian study. Breast Cancer Res Treat 2013; 141:101-110.
31. Perez EA, Romond EH, Suman VJ et al. Four year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 2011; 29:3366-3373.
32. Perez EA, Romond EH, Suman VJ et al. Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831. J Clin Oncol 2014; 32:3744-3752.
33. Mantovani A, Allavena P, Sica A., Balkwill F. Cancer-related inflammation. Nature 2008; 454:436-444.
34. Proctor MJ, McMillan DC, Morrison DS et al. A deriv-edneutrophil to lymphocyte ratio predicts survival in patients with cancer. Br J Cancer 2012; 107:695-699.
35. Ulich TR, Castillo J, Guo KZ. In vivo hematologic effects of recombinant interleukin-6 on hematopoiesis and circulating numbers of RBCs and WBCs. Blood 1989; 73:108-110.
36. Kusumanto YH, Dam WA, Hospers G.A., Meijer C., Mulder NH. Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor. Angiogenesis 2003; 6:283-287.
37. Donskov F. Immunomonitoring and prognostic relevance of neutrophils in clinical trials. Semin Cancer Biol 2013; 23:200-207.
38. Guthrie GJ, Charles KA, Roxburgh C.S., Horgan PG, McMillan C, Clarke SJ. The systemic inflammation-based neutrophil lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol 2013; 88:218-230.
39. Aizawa M, Gotohda N, Takahashi S., Konishi M, Kinoshita T. Predictive value of baseline neutrophil/lymphocyte ratio for T4 disease in wall-penetrating gastric cancer. World J Surg 2011; 35:2717-2722.
40. Yamanaka T, Matsumoto S, Teramukai S., Ishiwata R, Nagai Y, Fukushima M. The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in advanced gastric cancer. Oncology 2007; 73:215-220.
41. De Larco JE, Wuertz BR, Furcht LT. The potential role of neutrophils in promoting the metastatic phenotype of tumors releasing interleukin-8. Clin Cancer Res 2004; 10:4895-4900.
42. Clemente CG, Mihm MC, Jr., Bufalino R, Zurrida S, Collini P, Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996; 77:1303-1310.
43. Diederichsen AC, Hjelmborg JB, Christensen P.B., Zeuthen J., Fenger C. Prognostic value of the CD4+/CD8+ ratio of tumour infiltrating lymphocytes in colorectal cancer and HLA-DR expression on tumour cells. Cancer Immunol Immunother 2003; 52:423-428.
44. Zhang L, Conejo-Garcia JR, Katsaros D et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003; 348:203-213.
45. Sarraf KM, Belcher E, Raevsky E., Nicholson AG, Goldstraw P, Lim E. Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer. J Thorac Cardiovasc Surg 2009; 137:425-428.
46. Dvorak HF, Brown LF, Detmar M et al. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995; 146:1029-1039.
47. Benoy I, Salgado R, Colpaert C et al. Serum interleukin 6, plasma VEGF, serum VEGF, and VEGF platelet load in breast cancer patients. Clin Breast Cancer 2002; 2:311-315.
48. Nakano K, Hosoda M, Yamamoto M., Yamashita H. Prognostic significance of pre-treatment neutro-philymphocyte ratio in Japanese patients with breast cancer. Anticancer Res 2014; 34:3819-3824.
49. Bain B, Seed M, Godsland I. Normal values for peripheral blood white cell counts in women of four different ethnic origins. J Clin Pathol 1984; 37:188-193.
50. Queen MM, Ryan RE, Holzer R.G., Keller-Peck CR, Jorcyk CL. Breast cancer cells stimulate neutrophils to produce oncostatin M: potential implications for tumor progression. Cancer Res 2005; 65:8896-8904.
51. Eroles P, Bosch A, Pérez-Fidalgo JA, Lluch A. Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. Cancer Treat Rev 2012; 38:698-707.
52. Kennecke H, Yerushalmi R, Woods R et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol 2010; 28:3271-3277.
53. Place AE, Jin Huh S, Polyak K. The microenvironment in breast cancer progression: biology and implications for treatment. Breast Cancer Res 2011; 13:227.
54. Feigelson HS, Jonas CR, Teras L.R., Thun MJ, Calle EE. Weight gain, body mass index, hormone replacement therapy, and postmenopausal breast cancer in a large prospective study. Cancer Epidemiol Biomarkers Prev 2004; 13:220-224.
55. Koh YW, Lee HJ, Ahn J.H., Lee JW, Gong G. Prognostic significance of the ratio of absolute neutrophil to lymphocyte counts for breast cancer patients with ER/PR positivity and HER2 negativity in neoadjuvant setting. Tumour Biol 2014; 35:9823-9830.
56. Chua W, Charles KA, Baracos V.E., Clarke SJ. Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. Br J Cancer 2011; 104:1288-1295.
57. Holmes CE, Levis JE, Ornstein DL. Activated platelets enhance ovarian cell invasion in a cellular model of metastasis. Clin Exp Metastasis 2009; 26:653-661.